Massivemarkets

DNLI

Denali Therapeutics Inc. Common Stock

Nasdaq · usd

$18.41-0.25 (-1.34%)
At close · 15-minute delayed
$18.49+0.08 (+0.43%)
As of 7:30:05 PM EDT on Oct 23, 2026 · After hours

Denali Therapeutics Inc. Common Stock (DNLI) trades at $18.41 (-1.34%) as of 7:30:05 PM EDT on Oct 23, 2026, -10.06% over the past month. Market cap is $2.98B, with 7.6 days to cover in short interest.

Stock performance

How Denali Therapeutics Inc. Common Stock (DNLI) stock has performed from one day to one year, with its 52-week range.

+0.76%
+$0.14 over 1D
$18.07$18.25$18.44$18.624:00 AM10:40 AM12:35 PM2:25 PM8:00 PM$18.49
1D
-1.34%
1W
+4.54%
1M
-10.06%
YTD
+11.51%
1Y
+13.57%
52-wk range
$13.75 – $27.30

Key statistics

Today's trading snapshot for DNLI: day range, open, previous close, volume and market cap.

Day range
$18.01 – $18.50
Open
$18.49
Prev close
$18.66
Volume
1.01M
Market cap
$2.98B
Shares out
159.85M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Denali Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
827.62
P/B
3.57
P/FCF
—
ROE
-61.4%
ROA
-44.3%
Debt/Equity
0.01
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events Denali Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Deal completionsJul 28, 2026

    On July 27, 2026, Denali Therapeutics Inc. (the "Company") completed the previously disclosed sale (the "Sale") of its Rare Pediatric Disease Priority Review Voucher (the "PRV") to a large pharmaceutical company. Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $195.0 million from the buyer upon the closing of the Sale.

  • Deal completionsJun 18, 2026

    On June 12, 2026, Denali Therapeutics Inc. (the "Company") entered into an asset purchase agreement (the "PRV Transfer Agreement"), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher ("PRV")... Pursuant to the PRV Transfer Agreement, the buyer agreed to pay the Company $195 million, payable in cash, upon the closing of the sale.

  • Business developmentsMay 22, 2026

    On May 21, 2026, Denali Therapeutics Inc. (the "Company") and Biogen Inc. issued a press release announcing topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson's disease.

  • Deal terminationsApr 3, 2026

    On April 3, 2026, Denali Therapeutics Inc. received written notice from Takeda Pharmaceutical Company Limited of its decision to terminate the Collaboration Agreement, dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593. The termination will become effective 60 days following the notice date, at which time all rights in the DNL593 program will revert to Denali.

  • Business developmentsMar 31, 2026

    The closing followed the U.S. Food and Drug and Administration's accelerated approval of tividenofusp alfa on March 24, 2026.

DNLI short interest

How heavily DNLI is shorted: shares short, days to cover and average daily volume.

Days to cover
7.6
Short interest
15.46M
Avg volume
2.02M

As of · reported to FINRA twice monthly.

DNLI news

The latest news and headlines about Denali Therapeutics Inc. Common Stock (DNLI).

Frequently asked questions

What is the Denali Therapeutics Inc. Common Stock (DNLI) stock price today?

Denali Therapeutics Inc. Common Stock (DNLI) is trading at $18.41 (-1.34% on the day) as of 7:30:05 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Denali Therapeutics Inc. Common Stock?

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2…

What is the short interest in DNLI?

As of Sep 30, 2026, DNLI has 15.46M shares short and 7.6 days to cover.

What exchange is DNLI listed on?

Denali Therapeutics Inc. Common Stock (DNLI) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of DNLI with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a DNLI analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.